Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.
The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with "encouraging" initial safety and electroencephalography biomarker results.
The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.
Anavex said it expects to release topline data from the study in H2.
Price: 9.37, Change: -0.13, Percent Change: -1.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。